ATAI Life Sciences(ATAI) - 2025 Q3 - Quarterly Results

Financial Performance - AtaiBeckley reported a net loss of $61.1 million for Q3 2025, compared to a net loss of $26.3 million in Q3 2024, reflecting a significant increase in losses[14] - General and administrative (G&A) expenses rose to $14.5 million in Q3 2025, compared to $10.3 million in Q3 2024, largely due to increased legal and professional service expenses[12] - Research and development (R&D) expenses increased to $14.7 million in Q3 2025 from $12.4 million in the same period last year, driven by higher clinical program costs[11] Cash and Securities - The company had cash, cash equivalents, and short-term securities of $114.6 million as of September 30, 2025, up from $72.3 million at the end of 2024, primarily due to $148.8 million in net proceeds from equity issuances[10] - AtaiBeckley closed a public offering of common shares, generating approximately $150 million in gross proceeds, expected to fund operations into 2029[13] - Cash and cash equivalents rose to $30.40 billion, compared to $17.51 billion in December 2024, marking a 73.5% increase[23] Assets and Equity - Total assets increased to $239.82 billion as of September 30, 2025, up from $159.39 billion in December 2024, representing a growth of 50.4%[23] - Total stockholders' equity attributable to Atai Beckley N.V. stockholders increased to $159.75 billion from $116.30 billion, reflecting a growth of 37.3%[23] - Other investments held at fair value increased to $34.41 billion from $28.89 billion, a growth of 19.2%[23] Liabilities - Accounts payable increased to $5.37 billion, up from $2.62 billion, indicating a rise of 104.5%[23] - Pre-funded warrant liabilities reached $57.43 billion, with no previous balance reported in December 2024[23] - Current portion of long-term debt decreased to $0 from $6.37 billion, indicating a significant reduction in short-term liabilities[23] - Noncurrent portion of lease liabilities increased to $2.43 billion from $0.73 billion, reflecting a rise of 232.9%[23] Clinical Developments - BPL-003 received Breakthrough Therapy designation from the FDA for treatment-resistant depression, with positive Phase 2b data indicating sustained antidepressant effects after a second dose[4] - The company completed enrollment in the Phase 2a trial of EMP-01 for social anxiety disorder and anticipates topline results in Q1 2026[7] - The company is scheduled to have an End-of-Phase 2 meeting with the FDA for BPL-003, with guidance on the Phase 3 clinical program expected in Q1 2026[7] Grants and Funding - A multi-year grant worth up to $11.4 million was awarded by the National Institute on Drug Abuse to support the development of novel 5-HT2A/2C receptor agonists for opioid use disorder[8] Shareholder Information - The weighted average common shares outstanding attributable to AtaiBeckley N.V. stockholders increased to 217,601,496 in Q3 2025 from 160,621,817 in Q3 2024[21]